DnB Asset Management
TEVA icon

DnB Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

DnB Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.31M Buy
245,245
+11,350
+5% +$378K 0.02% 377
2026
Q1 		$7.04M Buy
233,895
+28,431
+14% +$915K 0.03% 367
2025
Q4 		$6.41M Hold
205,464
– – 0.02% 388
2025
Q3 		$4.15M Buy
205,464
+19,477
+10% +$342K 0.02% 468
2025
Q2 		$3.12M Sell
185,987
-2,911
-2% -$47K 0.01% 483
2025
Q1 		$2.9M Buy
188,898
+3,958
+2% +$70.7K 0.01% 494
2024
Q4 		$4.08M Buy
184,940
+21,727
+13% +$395K 0.02% 425
2024
Q3 		$2.94M Buy
163,213
+2,911
+2% +$50.9K 0.01% 504
2024
Q2 		$2.6M Buy
160,302
+14,001
+10% +$216K 0.01% 493
2024
Q1 		$2.06M Sell
146,301
-1,801
-1% -$22.7K 0.01% 527
2023
Q4 		$1.55M Hold
148,102
– – 0.01% 575
2023
Q3 		$1.51M Buy
148,102
+3,654
+3% +$34K 0.01% 582
2023
Q2 		$1.09M Hold
144,448
– – 0.01% 607
2023
Q1 		$1.28M Sell
144,448
-2,795
-2% -$27.6K 0.01% 597
2022
Q4 		$1.34M Sell
147,243
-8,900
-6% -$77.7K 0.01% 565
2022
Q3 		$1.26M Buy
156,143
+23,704
+18% +$210K 0.01% 566
2022
Q2 		$996K Hold
132,439
– – 0.01% 598
2022
Q1 		$1.24M Sell
132,439
-2,220
-2% -$18.5K 0.01% 596
2021
Q4 		$1.08M Buy
134,659
+7,154
+6% +$64.6K 0.01% 614
2021
Q3 		$1.24M Buy
127,505
+5,653
+5% +$52.9K 0.01% 597
2021
Q2 		$1.21M Hold
121,852
– – 0.01% 590
2021
Q1 		$1.41M Buy
121,852
+20,931
+21% +$240K 0.01% 573
2020
Q4 		$974K Buy
100,921
+20,354
+25% +$195K 0.01% 571
2020
Q3 		$726K Buy
80,567
+5,084
+7% +$53.8K 0.01% 559
2020
Q2 		$931K Hold
75,483
– – 0.01% 518
2020
Q1 		$678K Sell
75,483
-22,312
-23% -$229K 0.01% 536
2019
Q4 		$958K Buy
97,795
+12,533
+15% +$112K 0.01% 585
2019
Q3 		$587K Hold
85,262
– – 0.01% 594
2019
Q2 		$787K Buy
85,262
+8,379
+11% +$101K 0.01% 568
2019
Q1 		$1.21M Sell
76,883
-5,310
-6% -$93.6K 0.01% 512
2018
Q4 		$1.27M Buy
82,193
+3,189
+4% +$65.4K 0.02% 486
2018
Q3 		$1.7M Buy
79,004
+1,304
+2% +$30.3K 0.02% 439
2018
Q2 		$1.89M Buy
77,700
+9,300
+14% +$190K 0.02% 400
2018
Q1 		$1.17M Buy
68,400
+7,600
+13% +$148K 0.01% 474
2017
Q4 		$1.15M Hold
60,800
– – 0.01% 474
2017
Q3 		$1.07M Buy
60,800
+4,700
+8% +$106K 0.01% 467
2017
Q2 		$1.86M Sell
56,100
-17,500
-24% -$542K 0.03% 346
2017
Q1 		$2.36M Buy
73,600
+56,900
+341% +$1.94M 0.04% 301
2016
Q4 		$605K Sell
16,700
-86,015
-84% -$3.43M 0.01% 482
2016
Q3 		$4.73M Hold
102,715
– – 0.09% 167
2016
Q2 		$5.16M Hold
102,715
– – 0.11% 152
2016
Q1 		$5.5M Buy
102,715
+54,665
+114% +$3.21M 0.11% 144
2015
Q4 		$3.15M Buy
+48,050
New +$2.97M 0.07% 186
2015
Q2 		– Sell
-84,200
Closed -$5.24M – 472
2015
Q1 		$5.24M Buy
84,200
+36,200
+75% +$2.1M 0.12% 141
2014
Q4 		$2.76M Buy
+48,000
New +$2.67M 0.06% 188
2013
Q4 		– Sell
-11,966
Closed -$452K – 426
2013
Q3 		$452K Sell
11,966
-4,000
-25% -$156K 0.01% 354
2013
Q2 		$626K Buy
+15,966
New +$622K 0.02% 307

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

DnB Asset Management's TEVA Position: Q2 2026 in Review

DnB Asset Management increased its Teva Pharmaceuticals (TEVA) stake by 4.9% in Q2 2026, buying an estimated $378K and bringing the position to 245,245 shares worth $8.31M. The position accounts for 0.02% of the portfolio, ranked #377.

DnB Asset Management first reported a position in TEVA in Q2 2013 and has held it in 47 quarters since. 419 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • DnB Asset Management held 245,245 shares of Teva Pharmaceuticals worth $8.31M as of Q2 2026.
  • DnB Asset Management bought 11,350 Teva Pharmaceuticals shares in Q2 2026, an estimated $378K.
  • Teva Pharmaceuticals made up 0.02% of DnB Asset Management's portfolio in Q2 2026, its #377 holding.
  • DnB Asset Management first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 47 quarters since.
  • 419 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.